Only six new molecules were marketed during this period. Ganciclovir is the most welcome in the group, since it represents a step forward in the therapy of severe cytomegalovirus infections. In particular, it has been shown to slow the progression of chorioretinitis in 70/90 % of cases. Hematologic toxicity is the most important adverse reaction of ganciclovir and can require the suspension of therapy in up to 30% of patients. Alfuzosin is also of some interest, since it is the first drug marketed for the symptomatic treatment of prostatic hypertrophy that is supported by at least one clinical trial of acceptable quality. Confirmatory studies will be welcome. Flupirtine is a new central, non narcotic analgesic. It has been confronted with some antiinflammatory drugs and with pentazocine, showing a comparable efficacy. Adverse effects are frequent (about 25%), especially at the CNS level (vertigo, headache, insomnia). Nisoldipine is a calcium antagonist with little clinical documentation and no expected advantage over similar molecules with an already established role in therapy. Acetoxyethylcefuroxime is a pro-drug of cefuroxime, available for oral subministration. The risk of improper use for minor illnesses and of the development of resistances should be kept in mind. Verbenone is the latestin the long list of expectorants. We were not able to find any clinical documentation on this drug in our data banks.
|Translated title of the contribution||New drugs on the market: January - June 1991|
|Number of pages||8|
|Journal||Ricerca e Pratica|
|Publication status||Published - 1991|
ASJC Scopus subject areas